Journal of controlled release : official journal of the Controlled Release SocietyJul 9, 2025

Using low-frequency ultrasound to safely open the brain barrier for delivering RNA nanoparticles to brain tumors

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Apr 5, 2026

Abstract

A frequency of 850 kHz and 180 kPa pressure achieved a 10-fold increase in the delivery of lipid nanoparticles (LNPs) containing siRNAs to healthy brains.

Focused ultrasound combined with microbubbles can safely disrupt the blood-brain barrier (BBB) to facilitate drug delivery.
Different frequencies and pressures were tested to optimize conditions for BBB opening, with specific attention to maintaining microvascular integrity.
LNPs containing different ionizable lipids were compared, both showing success in delivering therapeutic agents across the BBB.
In a glioblastoma mouse model, LNPs with siRNAs demonstrated a 6.7-fold increase in fluorescence, indicating effective delivery to tumors.
Microscopy and bioluminescence techniques confirmed significant enhancements in the delivery of both small molecules and LNPs post-treatment.

Simplified

Ionizable Lipid Nanoparticles (LNP) are an FDA-approved non-viral RNA delivery system, though their use for brain therapy is restricted by the blood-brain barrier (BBB). Focused ultrasound combined with microbubbles can disrupt the BBB, but delivering large particles requires balancing increased peak negative pressures while maintaining microvascular integrity. Herein, we optimized low-frequency focused ultrasound (FUS) parameters to induce high-amplitude microbubble oscillations, enabling the safe delivery of LNPs across the BBB. First, BBB opening was assessed at different frequencies (850, 250, and 80 kHz) and pressures by monitoring the extravasation of Evans blue (∼1 kDa). Next, the delivery of 4, 70, and 150 kDa Dextrans, LNPs entrapping Cy5-siRNAs (∼70 nm in diameter), and LNPs entrapping mRNA (∼100 nm in diameter) was evaluated via microscopy and bioluminescence. Two types of LNPs containing different ionizable lipids (SM-102 and Lipid-14) were compared and both achieved successful brain delivery following FUS-mediated BBB opening. In a glioblastoma syngeneic mouse model, where the BBB remains largely intact under baseline conditions, siRNA-Cy5-LNP was successfully delivered. A frequency of 850 kHz and 180 kPa pressure induced safe BBB opening, enabling delivery of both small molecules and LNPs. In healthy brains, LNP entrapping siRNAs delivery increased 10-fold compared to controls, and LNPs with mRNAs showed a 12-fold increase in bioluminescence after 24 h. In glioblastoma tumors, LNPs with siRNAs delivery resulted in a 6.7-fold increase in fluorescence. This study paves the way for non-invasive LNP delivery to the brain, offering a versatile platform for brain therapies.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest D.P. receives licensing fees (to patents on which he was an inventor) from, invested in, consults (or on scientific advisory boards or boards of directors) for, lectured (and received a fee), or conducts sponsored research at TAU for the following entities: ART Biosciences, BioNtech SE, Earli Inc., Geneditor Biologics Inc., Kernal Biologics, Newphase Ltd., NeoVac Ltd., RiboX Therapeutics, SirTLabs Corporation, Teva Pharmaceuticals Inc. All other authors declare no competing financial interests.

PubMed

Using low-frequency ultrasound to safely open the brain barrier for delivering RNA nanoparticles to brain tumors

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief